Outcome of children with relapsed acute myeloid leukemia following initial therapy under the AML99 protocol

International Journal of Hematology

Volumn 100, Issue 2, 2014, Pages 171-179

  Nakayama, Hideki ^a   Tabuchi, Ken ^b   Tawa, Akio ^c   Tsukimoto, Ichiro ^d   Tsuchida, Masahiro ^e   Morimoto, Akira ^f   Yabe, Hiromasa ^g   Horibe, Keizo ^h   Hanada, Ryoji ⁱ   Imaizumi, Masue ^j   Hayashi, Yasuhide ^k   Hamamoto, Kazuko ^l   Kobayashi, Ryoji ^m   Kudo, Kazuko ⁿ   Shimada, Akira ^o   Miyamura, Takako ^p   Moritake, Hiroshi ^q   Tomizawa, Daisuke ^r   Taga, Takashi ^s   Adachi, Souichi ^t  

^a FUKUOKA HIGASHI MEDICAL CENTER   (Japan)

^b TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION   (Japan)

^d Saiseikai Kanagawa Hospital   (Japan)

^e Ibaraki Children's Hospital   (Japan)

^f JICHI MEDICAL UNIVERSITY   (Japan)

^g TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

ⁱ SAITAMA CHILDREN'S MEDICAL CENTER   (Japan)

^j MIYAGI CHILDREN S HOSPITAL   (Japan)

^k Gunma Children's Medical Center   (Japan)

^l ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^m SAPPORO HOKUYU HOSPITAL   (Japan)

ⁿ SHIZUOKA CHILDREN'S HOSPITAL   (Japan)

^o OKAYAMA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^p OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^q UNIVERSITY OF MIYAZAKI   (Japan)

^r TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^s SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^t KYOTO UNIVERSITY   (Japan)

more..

Author keywords

Acute myeloid leukemia (AML); Children; Hematopoietic stem cell transplantation (HSCT); Relapse; Second complete remission (CR2)

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CD135 ANTIGEN; CYTARABINE; ETOPOSIDE; IDARUBICIN; MITOXANTRONE;

ADOLESCENT; ALLOTRANSPLANTATION; CHILD; FEMALE; GENE DUPLICATION; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; METABOLISM; MORTALITY; PRESCHOOL CHILD; PROGNOSIS; RECURRENT DISEASE; REMISSION; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; CYTARABINE; ETOPOSIDE; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENE DUPLICATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IDARUBICIN; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; MITOXANTRONE; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84905901486     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-014-1616-9     Document Type: Article

References (38)

1. Tsukimoto I, Tawa A, Horibe K, Tabuchi K, Kigasawa H, Tsuchida M, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2009;27:4007-13.
2. Imamura T, Iwamoto S, Kanai R, Shimada A, Terui K, Osugi Y, et al. Outcome in 146 patients with pediatric acute myeloid leukemia treated according to the AML99 protocol in the period 2003-06 from the Japan Association of Childhood Leukemia Study. Br J Haematol. 2012;159:204-10.
3. Webb DKH, Wheatley K, Harrison G, Stevens RF, Hann IM, et al. Outcome for children with relapsed acute myeloid leukemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. Leukemia. 1999;13:25-31. (Pubitemid 29043713)
4. Aladjidi N, Auvrigno A, Leblanc T, Perel Y, Berard A, Bordigoni P, et al. Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology. J Clin Oncol. 2003;21:4377-85. (Pubitemid 46621815)
5. Wells RJ, Adams MT, Alonzo TA, Arceci RJ, Buckley J, Buxton AB, et al. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: children's Cancer Group Study 2951. J Clin Oncol. 2003;21(15):2940-7. (Pubitemid 46621845)
6. Abrahamsson J, Clausen N, Gustafsson G, Hovi L, Jonmundsson G, Zeller B, et al. Improved outcome after relapse in children with acute myeloid leukemia. Br J Haematol. 2007;136(2):229-36. (Pubitemid 46020750)
7. Sander A, Zimmermann M, Dworzak M, Fleischhack G, von Neuhoff C, Reinhardt D, et al. Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trails. Leukemia. 2010;24:1422-8.
8. Gorman MF, Ji L, Ko RH, Barnette P, Bostrom B, Hutchinson R, et al. Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a therapeutic advances in childhood leukemia (TACL) consortium study. Pediatric Blood Cancer. 2010;55(3):421-9.
9. Kaspers GJL, Zimmermann M, Reinhardt D, Gibson BES, Tamminga RYJ, Aleinikova O, et al. Improved outcome in pediatric acute myeloid leukemia: results of randomized trial on Liposomal Daunorubicin by the International BFM Study Group. J Clin Oncol. 2013;31(5):599-607.
10. Kanda Y. Investigation of the freely available easy-to-use software "EZR" (Easy R) for medical statics. Bone Marrow Transplant. 2013;48:452-8.
11. Taketani T, Taki T, Sugita K, et al. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood. 2004;103:1085-8. (Pubitemid 38129575)
12. Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001;31:187-90.
13. Shimada A, Taki T, Tabuchi K, Tawa A, Horibe K, Tsuchida M, et al. KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. Blood. 2006;107:1806-9. (Pubitemid 43289357)
14. Shimada A, Taki T, Tabuchi K, Taketani T, Hanada R, Tawa A, et al. Tandem duplication of MLL and FLT3 are correlated with poor prognoses in pediatric acute myeloid leukemia: a study of the Japanese childhood AML cooperative Study Group. Pediatr Blood Cancer. 2008;50(2):264-9.
15. Jamal R, Taketani T, Taki T, et al. Coduplication of the MLL and FLT3 genes in patients with acute myeloid leukemia. Genes Chromosomes Cancer. 2001;31:187-90. (Pubitemid 32411044)
16. Schnittger S, Wormann B, Hiddemann W, et al. Partial tandem duplications of the MLL gene are detectable in peripheral blood and bone marrow of nearly all healthy donors. Blood. 1998;92:1728-34. (Pubitemid 28406878)
17. Shimada A, Taki T, Koga D, Tabuchi K, Tawa A, Hanada R, et al. Low frequency of KIT mutations in pediatric acute myeloid leukemia with inv(16)(p13q22): a study of the Japanese Childhood AML Cooperative Study Group. Int J Hematol. 2007;86:289-90. (Pubitemid 350085823)
18. Sano H, Shimada A, Tabuchi K, Taki T, Murata C, Park MJ, et al. WT1 mutation in pediatric patients with acute myeloid leukemia: a report from the Japanese Childhood AML Cooperative Study Group. Int J Hematol. 2013;98:437-45.
19. Harrison CJ, Hills RK, Moorman AV, Grimwade DJ, Hann I, Webb DK, et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol. 2010;28(16):2674-81.
20. Von Neuhoff C, Reinhardt D, Sander A, Zimmermann M, Bradtke J, Betts DR, et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol. 2010;28(16):2682-9.
21. Creutzig U, van den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, de Bont E, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from international expert panel. Blood. 2012;120(16):3187-205.
22. Fleischhack G, Hassan C, Graf N, Mann G, Bode U. IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial. Br J Haematol. 1998;102(3):647-55. (Pubitemid 28387045)
23. Yalman N, Sarper N, Devecioǧlu O, Anak S, Eryilmaz E, Can M, et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAGIDA) for the treatment of relapsed or poor risk childhood acute leukemia. Turk J Pediatr. 2000;42(3):198-204.
24. Aplenc R, Alonzo TA, Gerbing RB, Lange BJ, Hurwitz CA, Wells RJ, et al. Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. J Clin Oncol. 2008;26:2390-5.
25. Zwaan CM, Reinhardt D, Zimmerman M, Hasle H, Stary J, Stark B, et al. Salvage treatment for children with refractory first or second relapse of acute myeloid leukemia with gemtuzumab ozogamicin: results of a phase II study. Br J Haematol. 2010;148(5):768-76.
26. Jeha S, Razzouk B, Rytting M, Rheingold S, Albano E, Kadota R, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Oncol. 2009;27(26):4392-7.
27. Becker PS, Kantarjian HM, Appelbaum FR, Petersdorf SH, Storer B, Pierce S, et al. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukemia. Br J Haematol. 2011;155(2):182-9.
28. Miano M, Pistorio A, Putti MC, Dufour C, Messina C, Barisone E, et al. Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients. Leuk Lymphoma. 2012;53(9):1693-8.
29. Davila J, Slotkin E, Renaud T. Relapsed and refractory pediatric acute myeloid leukemia: current and emerging treatments. Pediatr Drugs. 2014;16:151-68.
30. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, et al. Prognostic implication of Flt3 and N-ras gene mutations in acute myeloid leukemia. Blood. 1999;93:3074-80. (Pubitemid 29200800)
31. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98:1752-9.
32. Meshinchi S, Woods WG, Stirewalt DL, Sweetser DA, Buckley JD, Tjoa TK, et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood. 2001;97:89-94. (Pubitemid 32061246)
33. Zwaan CM, Meshinchi S, Radich JP, Veerman AJ, Huismans DR, Munske L, et al. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood. 2003;102:2387-94. (Pubitemid 37193574)
34. Shimada A, Taki T, Koga D, Tabuchi K, Tawa A, Hanada R, et al. High WT1 mRNA expression after induction chemotherapy and FLT3-ITD have prognostic impact in pediatric acute myeloid leukemia: a study of the Japanese Childhood AML Cooperative Study Group. Int J Hematol. 2012;96(4):469-76.
35. Fagioli F, Zecca M, Locatelli F, Lanino E, Uderzo C, Di Bartolomeo P, et al. Allogeneic stem cell transplantation for children with acute myeloid leukemia in second complete remission. J Pediatr Hematol Oncol. 2008;30:575-83.
36. Isoyama K, Oda M, Kato K, Nagamura-Inoue T, Kai S, Kigasawa H, et al. Long-term outcome of cord blood transplantation from unrelated donors as an initial transplantation procedure for children with AML in Japan. Bone Marrow Transplant. 2010;45:69-77.
37. The Japan Society for Hematopoietic Cell Transplantation Annual Report of Nationwide Survey 2012, JSHCT monograph, vol. 38, p. 97-127 (in Japanese), ISSN 1344-5898.
38. Rubnitz JE, Razzouk BI, Lensing S, Pounds S, Pui CH, Ribeiro RC. Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia. Cancer. 2007;109:157-63. (Pubitemid 46120203)